Article: Lupin Licenses US Rights for Proprietary Bioadhesive Technology for Rifaximin to Salix Pharmaceuticals.

Article: Salix Pharmaceuticals Acquires U.S. Right to Lupin's Proprietary ...
Business Wire;  October 5, 2009 ;     700+ words ... ... bioadhesive drug delivery technology for use with rifaximin. Salix and ... generation rifaximin product incorporating ... proprietary drug delivery platform with ... capabilities as a drug delivery provider ... R]) (rifaximin) Rifaximin ...

Article: Rifaximin to Control TravelersAE Diarrhea.
Internal Medicine Alert;  June 29, 2005 ;     700+ words ...Rifaximin to Control TravelersAE Diarrhea abstract ... AstraZeneca,and Centocor. Synopsis: Rifaximin, a newly released nonabsorbed antibiotic ... blind, placebo-controlled trial of rifaximin to prevent travelersAE diarrhea. Ann ...

Article: Rifaximin Demonstrates Highly Statistically Significant ...
Clinical Trials Week;  October 20, 2008 ;     700+ words ... ... efficacy, safety and tolerability of rifaximin in preventing hepatic encephalopathy ... endpoint comparison of a 6-month course of rifaximin at 550 mg dosed twice-a-day provides ... blind, placebo-controlled trial of rifaximin," stated Bill Forbes, Pharm.D ...

Article: A Rifaximin Review From The Medical Letter.
Travel Medicine Advisor;  December 1, 2004 ;     700+ words ...A Rifaximin Review From The Medical Letter Abstract ... Synopsis: The Medical Letter describes rifaximin as one alternative to a quinolone antibiotic ... preferred. Source: The Medical Letter. Rifaximin (Xifaxan)for Travellers Diarrhea ...

Article: Salix Presents New Rifaximin Phase IIb Data Demonstrating ...
Business Wire;  May 20, 2008 ;     700+ words ... ... analyses of the Phase IIb clinical trial of rifaximin, its non-absorbed, gut-selective ... 2008 showed that patients treated with rifaximin demonstrated statistically greater clinical ... safety profiles were similar between rifaximin and placebo. Improvements were sustained ...

Article: Salix Announces Positive Results from Rifaximin Antibiotic ...
Business Wire;  May 12, 2003 ;     700+ words ... ... a study analysis which concluded that rifaximin does not promote the resistance of gram ... or gram-positive intestinal flora. Rifaximin is a rifamycin derivative that is being ... submitted a New Drug Application (NDA) for rifaximin for the treatment of travelers' diarrhea ...

Article: Salix Begins Phase III Studies with Rifaximin.
BIOWORLD Today;  July 2, 2008 ;     700+ words ... ... to assess the efficacy and safety of rifaximin. The TARGET 1 and TARGET 2 (T-Targeted, nonsystemic; A-Antibiotic; R-Rifaximin; G-Gut-selective; E-Evaluation ... daily, 550-mg dosing regimen of rifaximin (a total of 1,650 mg/day) compared ...